Advisory Opinion Proceeding; Certain Sleep-Disordered Breathing Treatment Systems and Components Thereof; Institution of an Advisory Opinion Proceeding, 76320-76321 [2013-29887]

Download as PDF 76320 Federal Register / Vol. 78, No. 242 / Tuesday, December 17, 2013 / Notices Management California State Office, Sacramento, California, thirty (30) calendar days from the date of this publication. A copy of the plats may be obtained from the California State Office, Bureau of Land Management, 2800 Cottage Way, Sacramento, California 95825, upon required payment. Protest: A person or party who wishes to protest a survey must file a notice that they wish to protest with the California State Director, Bureau of Land Management, 2800 Cottage Way, Sacramento, California, 95825. FOR FURTHER INFORMATION CONTACT: Chief, Branch of Geographic Services, Bureau of Land Management, California State Office, 2800 Cottage Way, Room W–1623, Sacramento, California 95825, (916) 978–4310. SUPPLEMENTARY INFORMATION: These surveys were executed to meet the administrative needs of various federal agencies; the Bureau of Land Management, Bureau of Indian Affairs or Bureau of Reclamation. The lands surveyed are: ADDRESSES: wreier-aviles on DSK5TPTVN1PROD with NOTICES Mount Diablo Meridian, California T. 31 S., R. 16 E., dependent resurvey and metes-and-bounds survey accepted July 19, 2013. T. 23 S., R. 16 E., dependent resurvey and subdivision of section 28 accepted August 8, 2013. T. 6 N., R. 17 E., amended protraction diagram for unsurveyed area accepted August 9, 2013. T. 18 N., R. 11 W., dependent resurvey and subdivision accepted August 19, 2013. T. 21 N., R. 15 E., dependent resurvey and subdivision of sections accepted November 4, 2013. T. 45 N., R. 15 E., dependent resurvey and subdivision accepted November 4, 2013. T. 26 S., R. 36 E., dependent resurvey accepted November 8, 2013. T. 18 N., R. 1 W., metes-and-bounds survey accepted December 4, 2013. San Bernardino Meridian, California T. 1 S., R. 17 W., dependent resurvey, metesand-bounds survey and informative traverse accepted July 12, 2013. T. 7 S., R. 12 E., dependent resurvey, subdivision of sections and metes-andbounds survey accepted August 8, 2013. T. 8 S., R. 12 E., dependent resurvey, subdivision of sections and metes-andbounds survey accepted August 19, 2013. T. 9 S., R. 14 E., dependent resurvey and metes-and-bounds survey accepted August 19, 2013. T. 9 S., R. 13 E., dependent resurvey, subdivision of sections and metes-andbounds survey accepted August 20, 2013. T. 10 S., R. 14 E., dependent resurvey, subdivision of sections and metes-and- VerDate Mar<15>2010 14:45 Dec 16, 2013 Jkt 232001 bounds survey accepted September 18, 2013. T. 7 S., R. 13 E., dependent resurvey, subdivision of sections and metes-andbounds survey accepted September 18, 2013. T. 11 S., R. 15 E., dependent resurvey accepted September 19, 2013. T. 11 S., R. 16 E., dependent resurvey accepted September 19, 2013. T. 10 S., R. 18 E., dependent resurvey accepted September 19, 2013. T. 9 S., R. 16 E., dependent resurvey, subdivision of sections and metes-andbounds survey accepted September 19, 2013. T. 10 S., R. 15 E., dependent resurvey and metes-and-bounds survey accepted September 19, 2013. T. 12 S., R. 16 E., dependent resurvey and informative traverse accepted September 19, 2013. T. 11 S., R. 19 E., dependent resurvey and retracement accepted September 20, 2013. T. 13 S., R. 18 E., dependent resurvey, independent resurvey and subdivision of section accepted September 24, 2013. T. 12 S., R. 17 E., dependent resurvey and informative traverse accepted September 24, 2013. T. 9 S., R. 17 E., dependent resurvey, independent resurvey, subdivision of sections, informative traverse and metesand-bounds survey accepted September 25, 2013. T. 10 S., R. 19 E., dependent resurvey and independent resurvey accepted September 25, 2013. T. 12 S., R. 19 E., dependent resurvey and subdivision of section accepted September 25, 2013. T. 3 S., R. 1 E., supplemental plat of tract 52 in section 1 accepted November 14, 2013. T. 2 N., R. 5 W., dependent resurvey and subdivision of fractional sections 26, 27, 35, and 36 accepted November 21, 2013. T. 7 S., R. 12 E., supplemental plat of the S 1/2 of section 34 accepted November 26, 2013. T. 7 S., R. 12 E., supplemental plat of the S 1/2 of section 35 accepted November 26, 2013. T. 7 S., R. 12 E., supplemental plat of the SW 1/4 of section 36 accepted November 26, 2013. T. 7 S., R. 13 E., supplemental plat of section 31 accepted November 27, 2013. T. 7 S., R. 13 E., supplemental plat of sections 13 and 14 accepted November 27, 2013. T. 7 S., R. 13 E., supplemental plat of the NW 1/4 of section 22 accepted November 27, 2013. T. 8 S., R. 12 E., supplemental plat of section 2 accepted November 27, 2013. T. 10 S., R. 14 E., supplemental plat of the E 1/2 of the NE 1/4 of section 22 accepted November 27, 2013. Humboldt Meridian, California T. 12 N., R. 2 E., dependent resurvey, subdivision and survey accepted August 8, 2013. Authority: 43 U.S.C., Chapter 3. PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 Dated: December 9, 2013. Lance J. Bishop, Chief Cadastral Surveyor, California. [FR Doc. 2013–29943 Filed 12–16–13; 8:45 am] BILLING CODE 4310–40–P INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–879] Advisory Opinion Proceeding; Certain Sleep-Disordered Breathing Treatment Systems and Components Thereof; Institution of an Advisory Opinion Proceeding U.S. International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that the U.S. International Trade Commission has determined to institute an advisory opinion proceeding in the above-captioned investigation. FOR FURTHER INFORMATION CONTACT: Amanda Pitcher Fisherow, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–2737. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its Internet server at http://www.usitc.gov. The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at http:// edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission instituted the underlying investigation on April 25, 2013, based on a complaint filed on March 28, 2013, and supplemented on April 19, 2013, on behalf of ResMed Corp. of San Diego, California; ResMed Inc. of San Diego, California; and ResMed Ltd. of Australia (collectively, ‘‘ResMed’’). 78 FR 25475 (May 1, 2013). The complaint alleged violations of Section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, in the sale for importation, importation, or sale within the United States after importation of certain sleepdisordered breathing treatment systems and components thereof by reason of SUMMARY: E:\FR\FM\17DEN1.SGM 17DEN1 wreier-aviles on DSK5TPTVN1PROD with NOTICES Federal Register / Vol. 78, No. 242 / Tuesday, December 17, 2013 / Notices infringement of claims 1, 2, 4, 5, 17, and 28 of U.S. Patent No. 6,216,691, claims 1 and 20 of U.S. Patent No. 6,935,337, claim 15 of U.S. Patent No. 7,159,587, claims 1, 5, 6, 11, 12, 18–20, 35, and 36 of U.S. Patent No. 7,487,772, claims 1– 7 of U.S. Patent No. 7,614,398, claims 59, 60, 63, and 72–75 of U.S. Patent No. 7,743,767, and claims 17, 21–24, 29, and 32–37 of U.S. Patent No. 7,997,267. The Commission’s notice of investigation named as respondents Apex Medical Corp. of New Taipei City, Taiwan and Apex Medical USA Corp. of Brea, California (collectively, ‘‘Apex’’) and Medical Depot Inc., d/b/a Drive Medical Design & Manufacturing of Port Washington, New York. The Office of Unfair Import Investigations participated in the investigation. Medical Depot Inc. and Apex were previously terminated from the investigation on the basis of consent orders. Order Nos. 8 (unreviewed by the Commission, July 18, 2013) and 11 (unreviewed by the Commission, Aug. 8, 2013). On September 23, 2013, Apex filed a request with the Commission asking for institution of an advisory opinion proceeding to declare that their redesigned sleep-disordered breathing treatment systems are not covered by the consent order. Apex also requests that the proceeding be conducted expeditiously. ResMed filed a response on October 18, 2013 opposing Apex’s request. The Commission has determined that Apex’s request complies with the requirements for institution of an advisory opinion proceeding under Commission rule 210.79. Accordingly, the Commission has determined to institute an advisory opinion proceeding and referred Apex’s request to the Chief Administrative Law Judge to designate a presiding administrative law judge. The following entities are named as parties to the proceeding: (1) Complainant ResMed; (2) respondent Apex; (3) the Office of Unfair Import Investigations. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: December 11, 2013. Lisa R. Barton, Acting Secretary to the Commission. [FR Doc. 2013–29887 Filed 12–16–13; 8:45 am] BILLING CODE 7020–02–P VerDate Mar<15>2010 14:45 Dec 16, 2013 Jkt 232001 INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701–TA–503–504 and 731–TA–1229–1230 (Preliminary)] Monosodium Glutamate From China and Indonesia Determinations On the basis of the record 1 developed in the subject investigations, the United States International Trade Commission (Commission) determines, pursuant to sections 703(a) and 733(a) of the Tariff Act of 1930 (19 U.S.C. 1671b(a) and 1673b(a)) (the Act), that there is a reasonable indication that an industry in the United States is materially injured by reason of imports from China and Indonesia of monosodium glutamate, provided for in subheading 2922.42.10 of the Harmonized Tariff Schedule of the United States, that are alleged to be sold in the United States at less than fair value (LTFV) and subsidized by the Governments of China and Indonesia. Commencement of Final Phase Investigations Pursuant to section 207.18 of the Commission’s rules, the Commission also gives notice of the commencement of the final phase of its investigations. The Commission will issue a final phase notice of scheduling, which will be published in the Federal Register as provided in section 207.21 of the Commission’s rules, upon notice from the Department of Commerce (Commerce) of affirmative preliminary determinations in the investigations under sections 703(b) or 733(b) of the Act, or, if the preliminary determinations are negative, upon notice of affirmative final determinations in those investigations under sections 705(a) or 735(a) of the Act. Parties that filed entries of appearance in the preliminary phase of the investigations need not enter a separate appearance for the final phase of the investigations. Industrial users, and, if the merchandise under investigation is sold at the retail level, representative consumer organizations have the right to appear as parties in Commission antidumping and countervailing duty investigations. The Secretary will prepare a public service list containing the names and addresses of all persons, or their representatives, who are parties to the investigations. 1 The record is defined in sec. 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR § 207.2(f)). PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 76321 Background On September 16, 2013, a petition was filed with the Commission and Commerce by Ajinomoto North America Inc. (‘‘AJINA’’), Itasca, Illinois, alleging that an industry in the United States is materially injured or threatened with material injury by reason of LTFV imports of monosodium glutamate from China and Indonesia that are subsidized by the Governments of China and Indonesia. Accordingly, effective September 16, 2013, the Commission instituted countervailing duty investigation Nos. 701–TA–503–504 and antidumping duty investigation Nos. 731–TA–1229–1230 (Preliminary). Notice of the institution of the Commission’s investigations and of a public conference to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register of September 20, 2013 (78 FR 57881). The conference was held in Washington, DC, on October 23, 2013, and all persons who requested the opportunity were permitted to appear in person or by counsel. The Commission transmitted its determinations in these investigations to the Secretary of Commerce on November 18, 2013. The views of the Commission are contained in USITC Publication 4437 (November 2013), entitled Monosodium Glutamate from China and Indonesia: Investigation Nos. 701–TA–503–504 and 731–TA–1229– 1230 (Preliminary). By order of the Commission. Issued: November 19, 2013. Lisa R. Barton, Acting Secretary to the Commission. [FR Doc. 2013–29882 Filed 12–16–13; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [USITC SE–13–038] Government in the Sunshine Act Meeting Notice United States International Trade Commission. TIME AND DATE: December 17, 2013 at 11:00 a.m. PLACE: Room 101, 500 E Street SW., Washington, DC 20436, Telephone: (202) 205–2000. STATUS: Open to the public. MATTERS TO BE CONSIDERED: 1. Agendas for future meetings: None 2. Minutes AGENCY HOLDING THE MEETING: E:\FR\FM\17DEN1.SGM 17DEN1

Agencies

[Federal Register Volume 78, Number 242 (Tuesday, December 17, 2013)]
[Notices]
[Pages 76320-76321]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-29887]


=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-879]


Advisory Opinion Proceeding; Certain Sleep-Disordered Breathing 
Treatment Systems and Components Thereof; Institution of an Advisory 
Opinion Proceeding

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has determined to institute an advisory opinion proceeding 
in the above-captioned investigation.

FOR FURTHER INFORMATION CONTACT: Amanda Pitcher Fisherow, Esq., Office 
of the General Counsel, U.S. International Trade Commission, 500 E 
Street SW., Washington, DC 20436, telephone (202) 205-2737. Copies of 
non-confidential documents filed in connection with this investigation 
are or will be available for inspection during official business hours 
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW., Washington, DC 20436, 
telephone (202) 205-2000. General information concerning the Commission 
may also be obtained by accessing its Internet server at http://www.usitc.gov. The public record for this investigation may be viewed 
on the Commission's electronic docket (EDIS) at http://edis.usitc.gov. 
Hearing-impaired persons are advised that information on this matter 
can be obtained by contacting the Commission's TDD terminal on (202) 
205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted the underlying 
investigation on April 25, 2013, based on a complaint filed on March 
28, 2013, and supplemented on April 19, 2013, on behalf of ResMed Corp. 
of San Diego, California; ResMed Inc. of San Diego, California; and 
ResMed Ltd. of Australia (collectively, ``ResMed''). 78 FR 25475 (May 
1, 2013). The complaint alleged violations of Section 337 of the Tariff 
Act of 1930, as amended, 19 U.S.C. 1337, in the sale for importation, 
importation, or sale within the United States after importation of 
certain sleep-disordered breathing treatment systems and components 
thereof by reason of

[[Page 76321]]

infringement of claims 1, 2, 4, 5, 17, and 28 of U.S. Patent No. 
6,216,691, claims 1 and 20 of U.S. Patent No. 6,935,337, claim 15 of 
U.S. Patent No. 7,159,587, claims 1, 5, 6, 11, 12, 18-20, 35, and 36 of 
U.S. Patent No. 7,487,772, claims 1-7 of U.S. Patent No. 7,614,398, 
claims 59, 60, 63, and 72-75 of U.S. Patent No. 7,743,767, and claims 
17, 21-24, 29, and 32-37 of U.S. Patent No. 7,997,267. The Commission's 
notice of investigation named as respondents Apex Medical Corp. of New 
Taipei City, Taiwan and Apex Medical USA Corp. of Brea, California 
(collectively, ``Apex'') and Medical Depot Inc., d/b/a Drive Medical 
Design & Manufacturing of Port Washington, New York. The Office of 
Unfair Import Investigations participated in the investigation.
    Medical Depot Inc. and Apex were previously terminated from the 
investigation on the basis of consent orders. Order Nos. 8 (unreviewed 
by the Commission, July 18, 2013) and 11 (unreviewed by the Commission, 
Aug. 8, 2013).
    On September 23, 2013, Apex filed a request with the Commission 
asking for institution of an advisory opinion proceeding to declare 
that their redesigned sleep-disordered breathing treatment systems are 
not covered by the consent order. Apex also requests that the 
proceeding be conducted expeditiously. ResMed filed a response on 
October 18, 2013 opposing Apex's request.
    The Commission has determined that Apex's request complies with the 
requirements for institution of an advisory opinion proceeding under 
Commission rule 210.79. Accordingly, the Commission has determined to 
institute an advisory opinion proceeding and referred Apex's request to 
the Chief Administrative Law Judge to designate a presiding 
administrative law judge. The following entities are named as parties 
to the proceeding: (1) Complainant ResMed; (2) respondent Apex; (3) the 
Office of Unfair Import Investigations.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and 
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR 
part 210).

    By order of the Commission.

    Issued: December 11, 2013.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013-29887 Filed 12-16-13; 8:45 am]
BILLING CODE 7020-02-P